RE:RE:RE:RE:RE:Steady Accumulation, asks disappearing...You are correct OC this industry is in its infancy, with zero competition for InMed with its current Pipeline. What people do not understand is this is not your traditional Biotech Company taking the synthetic drug approach which as we know can become very expensive. InMed is taking the Non-Synthetic Approach, meaning it is a Quarter of the Cost and Quarter of Time to the Market Place. Also InMed is doing Multiple Therapies so their Eggs are not all in on 1 Basket. Soon this will not be a Vancouver Penny flipping Investor Crowd Buying this stock but an actual Wealthy, Sophisticated Biotech Network that truly grasps what InMed is doing different than the Rest of the Junior Biotech's out there. Enjoy your Saturday everyone, I'm off for a hike..Lifes too short to sit in front of your computer all weekend.